Oxaliplatin Pch 50, Oxaliplatin Pch 100 50 mg or 100 mg (5 mg/ml) Concentrate for solution for infusion
PDF Leaflet Revision Date: 12 January 2026
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of metastatic colorectal cancer and adjuvant treatment of colon cancer.
Dosage (summary)
85 mg/mu00b2 IV every 2 weeks for adults.
Special Populations
- Renal impairment
- Hepatic insufficiency
- Elderly patients
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding; teratogenic effects noted.
Key Drug Interactions
- Bone marrow depressants
- Anticoagulants
- Nephrotoxic medicines
- Ototoxic medicines
Contraindications
- Hypersensitivity to oxaliplatin
- Severe renal impairment
- Bone marrow failure
- Peripheral sensory neuropathy
- Pregnancy
- Breastfeeding
Common side effects
- Nausea
- Vomiting
- Diarrhoea
- Neutropenia
- Peripheral sensory neuropathy
Counselling Points
- Avoid cold exposure post-infusion
- Monitor for signs of infection
- Use effective contraception during treatment
Serious warnings
- Hypersensitivity reactions
- Neurological toxicity
- QT prolongation
- Rhabdomyolysis
- Gastrointestinal ulcer
Important Disclaimer
The Oxaliplatin Pch 50, Oxaliplatin Pch 100 50 mg or 100 mg (5 mg/ml) Concentrate for solution for infusion professional information leaflet below is the property of Teva Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
